Omeprazole + Domperidone Tablets

Mechanism

Omeprazole: Proton pump inhibitor that irreversibly blocks H+/K+ ATPase in gastric parietal cells, reducing acid secretion.
Domperidone: Dopamine (D2) receptor antagonist that enhances gastric emptying and provides antiemetic effect. The combination ensures acid suppression and improved gastric motility.

Pharmacodynamics:

Like other 2nd generation antihistamines, loratadine is selective for peripheral H1 receptors.Loratadine does not penetrate effectively into the central nervous system and has poor affinity for CNS H1-receptors.These qualities result in a lack of CNS depressant effects such as drowsiness, sedation, and impaired psychomotor function. The onset of action varies significantly and clinical efficacy is not always directly related to only the H1 receptor potency, as concentration of free drug at the receptor must also be considered.

Pharmacokinetics

• Absorption: Omeprazole rapidly absorbed; Domperidone bioavailability ~15%.
• Distribution: Both widely distributed; Domperidone protein binding ~90–95%.
• Metabolism: Omeprazole via CYP2C19 & CYP3A4; Domperidone via CYP3A4.
• Elimination: Omeprazole in urine; Domperidone in urine and feces.
• Half-life: Omeprazole ~1 hr; Domperidone ~7–9 hrs.

Side Effects

• Headache
• Dizziness
• Dry mouth
• Abdominal discomfort
• Diarrhea
• Rare: QT prolongation, arrhythmias

Contraindication

• Hypersensitivity to Omeprazole or Domperidone
• Severe hepatic impairment
• Cardiac conduction abnormalities (QT prolongation)
• Concomitant use with potent CYP3A4 inhibitors

Interaction

• Ketoconazole, erythromycin (increase Domperidone levels)
• Other QT-prolonging drugs
• Warfarin (Omeprazole may alter INR)

Warning and Precautions

• Use under medical supervision only
• Administer before meals for best effect
• Caution in elderly and patients with cardiac risk
• Consult physician during pregnancy and lactation

Dosage

As directed by the Physician.